Status:
COMPLETED
Safety, Blood Levels, Drug Interaction and Effects of Repeated Doses of GSK1034702
Lead Sponsor:
GlaxoSmithKline
Conditions:
Cognitive Disorders
Eligibility:
All Genders
18-64 years
Phase:
PHASE1
Brief Summary
GSK1034702 is being developed for improving cognitive impairment in diseases such as Alzheimer's disease and schizophrenia. This study will be done in healthy men and women of no child beading potenti...
Eligibility Criteria
Inclusion
- Male or female of non childbearing potential
- Generally healthy
- Body mass index 19 - 29.9 kg/m2 (inclusive), body weight greater than or equal to 50 kg for males and greater than of equal to 45 kg for females
- Normal Laboratory test results
Exclusion
- Abuse of drugs or alcohol
- Smoker or history of regular use of tobacco- or nicotine-containing products in the past 6 months
- ECG abnormality (personal or family history)
- Psychiatric disorder
- Asthma or a history of asthma
- Medical illness
Key Trial Info
Start Date :
August 24 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 24 2009
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT00950586
Start Date
August 24 2009
End Date
December 24 2009
Last Update
July 13 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
London, United Kingdom, NW10 7EW